You are here:

Forthcoming Submissions:

PACE medicines

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due
carfilzomib (Kyprolis) Amgen Ltd Full submission 3/04/2017 4/07/2017 7/08/2017
daratumumab (Darzalex) Janssen-Cilag Ltd Resubmission 31/07/2017 Q3 2017 Q4 2017
nivolumab (Opdivo) for Hodgkin lymphoma Bristol-Myers Squibb Pharmaceuticals Ltd Full submission 3/04/2017 6/06/2017 10/07/2017
nivolumab (Opdivo) SCCHN Bristol-Myers Squibb Pharmaceuticals Ltd Full submission 5/06/2017 1/08/2017 11/09/2017
olaratumab (Lartruvo) Eli Lilly and Company Ltd Full submission 31/07/2017 Q3 2017 Q4 2017
pembrolizumab (Keytruda) - 1st Line NSCLC MSD Full submission 3/04/2017 6/06/2017 10/07/2017
venetoclax (Venclyxto) AbbVie Ltd Full submission 1/05/2017 4/07/2017 7/08/2017

Non-PACE medicines

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due

Medicines with advice withheld pending product availability

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due

Back